{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:20Z","timestamp":1790803580355,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.critrevonc.2026.105156","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:08:19Z","timestamp":1769533699000},"page":"105156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Recent advances in systemic treatment for HER2-negative breast cancer with brain metastases"],"prefix":"10.1016","volume":"220","author":[{"given":"Chunfang","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105156_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215525","article-title":"Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy","volume":"2016","author":"Almajed","year":"2016","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105156_bib2","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105156_bib3","doi-asserted-by":"crossref","first-page":"GS02","DOI":"10.1158\/1538-7445.SABCS23-GS02-01","article-title":"Abstract GS02-01: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: results from TROPION-Breast01","volume":"84","author":"Bardia","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105156_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103209","article-title":"187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)","volume":"9","author":"Bartsch","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105156_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00639","article-title":"Analysis of breast cancer brain metastases reveals an enrichment of cyclin-dependent kinase 12 structural rearrangements in human epidermal growth factor receptor 2-positive disease","author":"Bhogal","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib6","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105156_bib7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer-capivasertib-fulvestrant: ASCO rapid recommendation update","volume":"42","author":"Burstein","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/annonc\/mdu488","article-title":"Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer","volume":"26","author":"Cao","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib9","article-title":"PD-L1 expression in breast cancer brain metastases","volume":"4","author":"Chehade","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.critrevonc.2026.105156_bib10","article-title":"The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases","volume":"55","author":"Chen","year":"2023","journal-title":"Ann. Med."},{"key":"10.1016\/j.critrevonc.2026.105156_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-023-06910-6","article-title":"Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis","volume":"199","author":"Cheng","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105156_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114175","article-title":"Impact of cyclin dependent kinase 4\/6 inhibitors on breast cancer brain metastasis outcomes","volume":"207","author":"Chew","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105156_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-017-4304-7","article-title":"Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial","volume":"165","author":"Cort\u00e9s","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105156_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102324","article-title":"Targeting brain metastases in breast cancer","volume":"103","author":"Corti","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105156_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102995","article-title":"The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis","volume":"9","author":"Dannehl","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105156_bib17","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1080\/0284186X.2023.2260942","article-title":"Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis","volume":"62","author":"Depner","year":"2023","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib18","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO-25-00812","volume":"43","author":"Dilawari","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib19","doi-asserted-by":"crossref","first-page":"S656","DOI":"10.1016\/j.annonc.2022.07.299","article-title":"260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial","volume":"33","author":"Epaillard","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib20","first-page":"i6","article-title":"BSLM-07 a first in human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (CDC1S) primed against HER2\/HER3 in patients (PTS) with leptomeningeal disease (LMD) from triple negative (TNBC) OR HER2+ breast cancer (BC)","volume":"6","author":"Forsyth","year":"2024","journal-title":"NeuroOncol. Adv."},{"key":"10.1016\/j.critrevonc.2026.105156_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ijc.33243","article-title":"Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson cancer center experience","volume":"148","author":"Gao","year":"2021","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105156_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122927","article-title":"Brain metastases in HER2-positive breast cancer: current and novel treatment strategies","volume":"13","author":"Garcia-Alvarez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105156_bib23","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/neuonc\/noac136","article-title":"A comprehensive profiling of the immune microenvironment of breast cancer brain metastases","volume":"24","author":"Griguolo","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-025-00736-9","article-title":"Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases","volume":"11","author":"Grinda","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105156_bib25","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105156_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2023.07.005","article-title":"Brain metastasis in de novo stage IV breast cancer","volume":"71","author":"He","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105156_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","article-title":"Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"10","author":"Hurvitz","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105156_bib28","first-page":"26","article-title":"23 ELECTRA: an open-label, multicenter, phase 1b\/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor\u2013positive (ER+), HER2-negative (HER2) breast cancer (BC)","volume":"38","author":"Ibrahim","year":"2024","journal-title":"Miami Breast Cancer Conf. \u00ae Abstr. Suppl."},{"key":"10.1016\/j.critrevonc.2026.105156_bib29","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.24.00110","article-title":"Phase I\/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105156_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","article-title":"Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases","volume":"29","author":"Kabraji","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105156_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091649","article-title":"The safety and efficacy of the combination of sacituzumab govitecan and palliative radiotherapy-a retrospective multi-center cohort study","volume":"16","author":"Krug","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105156_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12052044","article-title":"Efficacy of CDK 4\/6 inhibitors and radiotherapy in breast cancer patients with brain metastases","volume":"12","author":"Kubeczko","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105156_bib35","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib36","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105156_bib37","doi-asserted-by":"crossref","first-page":"ii87","DOI":"10.1093\/neuonc\/noaa215.358","article-title":"Exth-04. Intrathecal (It) delivery of type I polarized dendritic cell vaccine (Dc1) eradicates tumor growth in breast cancer (Bc) xenograft model with brain metastases (bm) and leptomeningeal disease (Lmd)","volume":"22","author":"Law","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-019-05445-z","article-title":"A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases","volume":"179","author":"Leone","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105156_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13058-020-01372-w","article-title":"Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases","volume":"22","author":"Leone","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105156_bib41","article-title":"A phase II trial combining SHR-1316, bevacizumab, and cisplatin\/carboplatin in patients with TNBC with active brain metastases","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib42","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib43","article-title":"Efficacy and safety of anlotinib for triple-negative breast cancer with brain metastases","volume":"14","author":"Liu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/jco.2012.30.15_suppl.1079","article-title":"Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: results of the first stage of a multicenter phase II study","volume":"30","author":"Lu","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102389","article-title":"Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population","volume":"9","author":"Lu","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105156_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2024.42.23_suppl.2","article-title":"Updated efficacy of anti-TROP2 ADC ESG401 for first-line metastatic TNBC in phase 1b study","volume":"42","author":"Ma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib47","article-title":"344MO ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases","volume":"35","author":"Ma","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib48","doi-asserted-by":"crossref","first-page":"P4-01-23","DOI":"10.1158\/1538-7445.SABCS22-P4-01-23","article-title":"Abstract P4-01-23: Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer","volume":"83","author":"McAndrew","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105156_bib49","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-6-6","article-title":"Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis","volume":"10","author":"Mollica","year":"2021","journal-title":"Drugs Context"},{"key":"10.1016\/j.critrevonc.2026.105156_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040965","article-title":"Intracranial response rate in patients with breast cancer brain metastases after systemic therapy","volume":"14","author":"Niwinska","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105156_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112134","article-title":"Prevention of brain metastases: a new frontier","volume":"16","author":"Pellerino","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105156_bib52","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","article-title":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial","volume":"31","author":"Preusser","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105156_bib53","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/OP.23.00794","article-title":"Breast cancer brain metastasis: a comprehensive review","volume":"20","author":"Raghavendra","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.critrevonc.2026.105156_bib54","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105156_bib55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11060-024-04788-y","article-title":"Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression","volume":"170","author":"Rogawski","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.critrevonc.2026.105156_bib56","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.34525","article-title":"Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial","volume":"153","author":"Senkus","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105156_bib57","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer","volume":"28","author":"Shah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105156_bib58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-017-2572-z","article-title":"Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis","volume":"135","author":"Tian","year":"2017","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib61","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.2017.35.15_suppl.1019","article-title":"Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer","volume":"35","author":"Tolaney","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib62","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105156_bib63","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-23-0020","article-title":"Frequent overexpression of HER3 in brain metastases from breast and lung cancer","volume":"29","author":"Tomasich","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105156_bib64","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2022.0514","article-title":"Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial","volume":"8","author":"Tripathy","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib65","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/j.annonc.2023.09.565","article-title":"388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC)","volume":"34","author":"Tsurutani","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib66","doi-asserted-by":"crossref","unstructured":"J. Tsurutani, W J., T. Yamashita, et al. (Annals of Oncology 2023 34 (suppl_2): S334-S390. 10.1016\/S0923-7534(23)01260-7). Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC).","DOI":"10.1016\/j.annonc.2023.09.565"},{"key":"10.1016\/j.critrevonc.2026.105156_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103757","article-title":"Comprehensive analysis of stereotactic Radiosurgery outcomes in triple-negative breast cancer patients with brain metastases: the influence of immunotherapy and prognostic factors","volume":"76","author":"Turna","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105156_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40478-025-02001-3","article-title":"Genomic and immune profiling of breast cancer brain metastases","volume":"13","author":"Van Swearingen","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.critrevonc.2026.105156_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103699","article-title":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","volume":"9","author":"Vaz Batista","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105156_bib70","article-title":"The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis","volume":"6","author":"Vaz Batista","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2026.105156_bib71","article-title":"Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review","author":"Wallace","year":"2023","journal-title":"Res Sq."},{"key":"10.1016\/j.critrevonc.2026.105156_bib72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","article-title":"Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor","volume":"22","author":"Xiong","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105156_bib73","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-022-06785-z","article-title":"Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study","volume":"197","author":"Xu","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105156_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf174","article-title":"Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study","volume":"30","author":"Xue","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105156_bib75","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.2024.42.16_suppl.1081","article-title":"Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study","volume":"42","author":"Yan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib76","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jamaoncol.2025.1694","article-title":"Utidelone plus bevacizumab for ERBB2-negative metastatic breast cancer and active brain metastases: the U-BOMB phase 2 nonrandomized clinical trial","volume":"11","author":"Yan","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105156_bib77","doi-asserted-by":"crossref","unstructured":"Yin, Y., et al. 2025. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. \u3008https:\/\/meetings.asco.org\/abstracts-presentations\u3009.","DOI":"10.1200\/JCO.2025.43.16_suppl.1019"},{"key":"10.1016\/j.critrevonc.2026.105156_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231206986","article-title":"Combination of palbociclib and endocrine therapy in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer with or without brain metastases","volume":"23","author":"Zhang","year":"2024","journal-title":"Technol. Cancer Res. Treat."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:58:36Z","timestamp":1776974316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":78,"alternative-id":["S1040842826000430"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105156","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in systemic treatment for HER2-negative breast cancer with brain metastases","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105156"}}